Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) | PAR 19 242

Opportunity Information: Apply for PAR 19 242

The Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional), Funding Opportunity Number PAR-19-242, is an NIH discretionary grant mechanism designed to support structured career development in clinical oncology through an institutional K12 program. In practice, this type of award is made to an eligible institution, which then uses the funding to appoint and support "Scholars" who are early in their careers and are building the skills, experience, and publication record needed to become independent clinical oncology investigators. The central purpose is to create a mentored environment with protected time and resources so Scholars can develop as researchers while advancing clinically relevant oncology studies.

A notable feature of this announcement is its flexibility around clinical trials. The FOA explicitly permits appointment of Scholars who will (1) serve as the lead investigator of an independent clinical trial, (2) lead an ancillary study that is tied to an existing clinical trial, or (3) gain hands-on research experience by participating in a clinical trial that is led by another investigator. In other words, the program can accommodate different levels of trial leadership and responsibility, ranging from full trial leadership to embedded training within an established trial team, as long as the trial-related work is integrated into the Scholar's research and overall career development plan.

The opportunity falls under the Funding Activity Category of Education and Health and is associated with CFDA number 93.398. As a K12, it is intended to strengthen the clinical oncology research workforce by supporting training in rigorous clinical research methods, mentorship, and the development of a coherent research trajectory that can later compete successfully for individual career development awards or independent research grants.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; and a range of nonprofit and for-profit entities (including small businesses and for-profit organizations other than small businesses). The FOA also highlights additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. This emphasis signals that NIH is open to a wide variety of institutional settings that can provide a strong mentored clinical research environment in oncology.

The announcement also draws a clear line on foreign eligibility. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed, meaning a U.S. applicant institution may include certain well-justified international elements or collaborations within NIH policy boundaries, even though the applicant organization itself must be U.S.-based.

The listed agency is the National Institutes of Health. The source data indicates an original closing date of 2021-06-17 and a creation date of 2019-04-08. Award ceiling and expected awards are not specified in the provided summary, which is common in some NIH listings where budgets and number of awards can vary based on appropriations, institute participation, and the scope of the proposed institutional training program.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.398.
• This funding opportunity was created on 2019-04-08.
• Applicants must submit their applications by 2021-06-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 242

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: